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Drug resistance threatens many critical therapeutics through mutations in the drug target. The 
molecular mechanisms by which combinations of mutations, especially involving those distal from 
the active site, alter drug binding to confer resistance are poorly understood and thus difficult to 
counteract. A strategy coupling parallel molecular dynamics simulations and machine learning to 
identify conserved mechanisms underlying resistance was developed. A series of 28 HIV-1 
protease variants with up to 24 varied substitutions were used as a rigorous model of this 
strategy. Many of the mutations were distal from the active site and the potency to darunavir 
varied from low pM to near µM. With features extracted from molecular dynamics simulations, 
elastic network machine learning was applied to correlate physical interactions at the molecular 
level with potency loss. This fit to within 1 kcal/mol of experimental potency for both the training 
and test sets, outperforming MM/GBSA calculations. Feature reduction resulted in a model with 4 
specific features that correspond to interactions critical for potency regardless of enzyme variant. 
These predictive features throughout the enzyme would not have been identified without 
dynamics and machine learning and specifically varied with potency.  This approach enables 
capturing the conserved dynamic molecular mechanisms by which complex combinations of 
mutations confer resistance and identifying critical interactions which serve as bellwethers over a 
wide range of inhibitor potency. Machine learning models leveraging molecular dynamics can 
thus elucidate mechanisms that confer loss of affinity due to variations distal from the active site, 
such as in drug resistance. 
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Drug resistance is ubiquitous in both infectious diseases and oncology, impeding the success of 
drug therapy and severely impacting human health. (1, 2) Mechanisms that confer drug 
resistance are manifold and include reduced cellular uptake, degradation, and changes in target 
expression. (1) Often drug resistance is caused by mutations that disrupt drug–target interactions 
while preserving the target’s function in the presence of drug. Drug resistance due to loss of 
drug–target interactions is particularly prevalent in viruses and low complexity organisms that do 
not possess the genomic capacity to encode for auxiliary resistance genes but occurs in all 
quickly evolving drug targets. (3-5) 
 
HIV-1 is one of the most rapidly evolving viruses and treatment of HIV-1 infections has historically 
been severely affected by drug resistance. (6, 7) The fast rate of mutation and abundance of 
experimental data make HIV-1 protease an ideal model system to elucidate the molecular 
mechanisms by which mutations cause resistance. Structural studies on HIV-1 protease and drug 
resistance have led to the development of the substrate envelope hypothesis, which postulates 
that competitive active site inhibitors can avoid resistance by maximizing shape similarity with the 
native substrates. (8) The success of this strategy has been demonstrated not only in HIV-1 
protease but also in other rapidly evolving viral targets. (9, 10) The most recently FDA approved 
HIV-1 protease inhibitor darunavir (DRV) adheres to this strategy, resulting in a remarkably high 
barrier to resistance. Resistance to DRV still emerges through accumulation of multiple mutations 
both proximal and distal from the active site. (11-14) Elucidating the resistance mechanism for 
very potent inhibitors, such as the HIV-1 protease inhibitor DRV, provides insights into how amino 
acid substitutions alter the structure, dynamics and function of a therapeutic target. (15, 16) 
However the molecular mechanisms by which mutations, in particular those distal from the active 
site, confer resistance remains elusive. 
 
A common assumption is that these distal mutations are required to retain structural stability and 
enzymatic activity by compensating for otherwise deleterious active site mutations. (17, 18) 
However in-depth studies of highly resistant drug resistant protease variants indicate that distal 
mutations can also alter drug–target interactions through propagating dynamic alterations within 
the network of intra-protein interactions, as proposed by the “network hypothesis”. (19, 20) 
Consistent with this, NMR studies indicate that drug resistant variants show distinct changes in 
protein dynamics. (21) Our initial regression models where we examined one physical feature at a 
time also indicated that dynamics were likely the key in resistance (22, 23). We previously 
characterized a series of increasingly drug resistant protease variants from viral passaging 
experiments and through co-crystal structures, enzyme inhibition and molecular dynamics (MD) 
simulations demonstrated that variants with mutations distal from the active site weakened 
interactions with the inhibitor through changes in structure and dynamics. (24)   
 
Although enzyme–inhibitor dynamics are known to be critical in resistance especially due to 
mutations distal from the active site, the molecular mechanisms involved are not clear. 
Resistance may be conferred through dynamic changes specific to a given variant, or through 
conserved mechanisms that can be captured by a comprehensive analysis of an enzyme–
inhibitor system. Identifying such conserved mechanisms would enable predicting the cause of 
drug resistance and designing more robust inhibitors to avoid resistance. Here we systematically 
probe the ensemble dynamics of HIV-1 protease variants with increasing levels of resistance, to 
elucidate the molecular mechanisms of drug resistance. Based on features calculated from 
molecular dynamics simulations, machine learning was used to construct a model correlating 
physical interactions at the molecular level with the loss of inhibitor potency. We found that as few 
as four physical features were sufficient to describe the observed changes in binding affinity 
across a broad range of HIV-1 protease variants. These physical features include direct 
interactions between protease and inhibitor, as well as intra-molecular contacts between distal 
protein residues which likely anchor the protease in the closed, inhibited conformation. The 
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accuracy of the resulting model exceeds that of endpoint free energy calculations, which fail to 
account for the impact of distal changes. The predictive accuracy of the model was further 
validated on a separate test set of protease variants not used in building the model. Machine 
learning models identifying and leveraging such “bellwether” interactions can thus strongly 






A set of 28 HIV-1 protease variants was chosen to cover a wide range of darunavir (DRV) 
susceptibility and resistance, over six orders of magnitude in potency. The variants included up to 
24 mutations each, with substitutions in 48 of the 99 residues within the enzyme. (Fig 1; Fig. S1). 
The number and distribution of the amino acid substitutions are in excellent agreement with 
protease variants observed in clinical isolates. (25) The spatial distribution of mutations (Fig. 1A) 
highlights the remarkable genomic plasticity of HIV-1 protease; contiguous regions without 
changes are found only surrounding the catalytic site and at the terminal dimerization motif. As 
HIV-1 protease is a homodimer (residues on either of the two monomers are indicated by a 
subscript A or B below) each mutation has a double impact. Only a few sites had  ≥3 substitutions 
(Fig. 1B) including the polymorphic residues 63 and 89 and three resistance-associated sites 10, 
54 and 82. (26, 27) Most substitutions in these resistant variants are distal from the inhibitor 
binding site.    
 
The protease variants clustered into 3 major subgroups based on amino acid sequence. (Fig 1C, 
Table 1) Cluster 3 included all variants obtained from viral passaging experiments with DRV and 
DRV analogs (14). Cluster 2 included variants with less than 5 amino acid substitutions. Finally, 
cluster 1 included all protease variants obtained from clinical isolates. Cluster 1 was by far the 
most diverse, having a mean sequence identity of 80% with the remaining protease variants (11, 
28). Despite the larger mutational load, the clinical isolates were not more resistant to DRV than 
the variants obtained from viral passaging. In fact, the number of substitutions was only weakly 
correlated with DRV potency. Variants with less than 5 mutations were significantly more 
susceptible to DRV; however, for the clinical isolates and for variants obtained from viral 
passaging experiments, no simple relationship could be established between the number of 
substitutions and susceptibility to DRV. 
 
Feature Selection: Determination of Specific Features 
 
To characterize changes in interactions and dynamics across the HIV-1 protease variants, 100 ns 
simulation of all 28 variants were performed in triplicates.  A total of 2858 features were 
calculated from molecular dynamics simulations for each complex.  These features included van 
der Waals (vdW) interactions, hydrogen bonds, torsion angle entropy and root mean squared 
fluctuations. As molecular features also contain information about amino acid sequence identity, a 
critical test was to see whether the effect of any given molecular feature could equally be 
explained by the mere presence of a particular sequence mutation. Molecular features that 
substitute for sequence information decrease the specificity of the model, as sequence alone 
does not ascertain which specific physical changes occur at the molecular level. Such features 
would also reduce the generalizability of the model, as only a limited number of amino acid 
combinations can be included in building the model.  
 
For regression analysis a parsimonious set of features is generally desirable, to improve the 
model accuracy and interpretability. (29) Therefore only the subset of features that strongly 
impact potency were selected. Features were selected according to three criteria: Accuracy, 
Stability and Specificity. Accuracy requires the features to be strongly correlated with the 
observed binding affinity. Stability requires that the weight of a feature be unaffected by relatively 
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minor perturbations in the data. Finally, specificity requires that the feature inform on the 
relationship between changes in molecular interactions and changes in potency. Accuracy and 
stability were achieved by using regularized regression model on a subset (66%) of the training 
set and repeating this process on random permutations of the entire training set of variants.  
Features were defined to be specific when they provided more information on inhibitor potency 
than an alternative regression model trained on amino acid sequence information alone. 
 
Elastic net regression was used to identify which among the 2858 features best correlated with 
the observed potency. The model was fit to two thirds of the training data while one third was left 
for model evaluation. To ensure convergence of the resulting coefficients, this process was 
repeated 100 times with random permutations of the dataset. 59 features with non-zero 
coefficients (p<0.05; 1 sample t-test) were identified. When sorted, the mean absolute coefficients 
exhibited an exponential decay with the knee of the curve located at 0.02. (Fig. 2A) Only 9 of the 
selected features had coefficients above 0.2, which are anticipated to be the most correlated with 
potency.  
 
The 9 remaining features included 5 intra-protein vdW interactions, the root-mean-squared 
fluctuations of one inhibitor nitrogen atom (RMSF DRV12), two torsion angles (92B ψ and 45B ψ), 
and the hydrogen bond between the catalytic residues and inhibitor (Hbond D25). Except for 
RMSF DRV12, 92B ψ and Hbond D25, all features involved at least one variable residue. The 9 
selected features could be separated into two distinct clusters based on their correlation with one 
another indicating the complexity of their interdependence. (Fig. 2B) Physically, when mapped 
onto the protein structure, the residues involved in the interactions formed a contiguous region 
bisecting the protease dimer diagonally from the “flap”, through the active site, to the outer loops 
of the dimer. (Fig. 2C) Interestingly, on the protein structure these features have an asymmetric 
arrangement. HIV-1 protease is a homodimer; however, asymmetry is introduced when a non-
symmetric inhibitor is bound. To establish whether the observed asymmetry is a determining 
factor or the result of a random selection process, all symmetry related features were swapped 
(e.g. 92B ψ → 92A ψ). DRV12 and H-Bond D25 were kept the same as there is no symmetry-
related counterpart.  The symmetry swapped model performed significantly worse than the 
original model, confirming that the features are specific to one protein chain. Most of the specific 
features involved hydrophobic residues. Rearrangements in the hydrophobic core, or hydrophobic 
sliding, of the protease has previously been proposed by us as a potential mechanism by which 
distal mutations alter inhibitor interactions to confer resistance. (30, 31) Our findings not only 
corroborate these results, but the selected features also indicate the key interactions associated 
with such changes that translate to alterations in potency.  
 
Predictive Models of Potency 
 
The best model to predict potency using the 9 selected features with the least possible 
parameters was then determined. The features retained significant collinearity, implying potential 
redundancy or interdependency. (Fig. 2B) All 511 feature combinations were evaluated to 
converge on the final model. After discarding all combinations with a relative likelihood of 
minimizing the information loss < 0.05 (See Methods, Eq. 3 and Eq. 4), the final model was 
chosen by minimizing the number of parameters and maximizing the coefficient of determination 
(r2). This model included only 4 features (vdW 12B-13B, vdW 10B-24B, vdW 50B-84A and HBond 
D25). Using 5-fold cross validation, the root mean squared error (RMSE) of the model with these 
4 features on the training set was 0.9 kcal/mol, Pearson correlation was 0.9 and Spearman 
correlation 0.8. (Fig. 3) On the independent test set, the RMSE was 1.3 kcal/mol and correlation 
coefficients dropped to 0.6 and 0.5. (Fig. 3) The performance on the test set captures the 
predictive ability and generalizability of the model. Including more than 4 parameters did not 
improve the fit. In fact, including all 9 parameters in the model significantly increased the variance 
of the predictions and only had a marginal effect on the r2: RMSE on the training and test sets 
decreased to 1.2 kcal/mol and 1.5 kcal/mol respectively, with worse p-values (>0.05). Thus, the 
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model with 4 parameters performed the best. This level of accuracy was reassuring of physical 
reasonableness of the model since the parameters were selected using the full training set and 
the model could translate predictive power to naïve data. 
 
To compare the performance of our model with methods commonly used to evaluate ligand 
affinity, the binding free energy of DRV was calculated using MM/GBSA. (32, 33) Endpoint 
methods such as MM/GBSA are agnostic to dynamics and merely compare the free energy of the 
bound and unbound states. This method has been previously used to evaluate the impact of 
amino acid substitutions in HIV-1 protease. (34) MM/GBSA is historically performed on a single 
conformation, mostly with the inhibitor docked to a protein crystal structure. For a single structure, 
MM/GBSA scores did not correlate with the binding potency (ρPearson: 0.33; p: 0.001). To attempt a 
comparison that also includes dynamics, the binding free energy was calculated in 1 ns intervals 
during every MD simulation (3 replicates of 100 ns), and averaged over the resulting 300 
calculations per protease variant. This resulted in a far better (ρPearson: 0.58; p: 0.001) correlation 
between the experimental potency and the binding free energy calculated from MM/GBSA, 
validating that dynamics is key to characterizing potency. (Fig. 4) Previous studies that combined 
MD and MM/GBSA typically used much shorter simulations (4–40 ns) and had low accuracy to 
fitting the data. (35, 36) The most resistant variant was a notable outlier in the MM/GBSA 
calculations even with dynamics included. We have characterized this variant extensively in the 
past and found its conformational dynamics to deviate significantly from those of other protease 
variants. (24) Because this highly resistant variant samples a broader distribution of the bound 
states, the average free energy deviates significantly from the other estimates. Overall, even 
though the free energy calculations performed better when averaged over a set of snapshots 
from the MD simulations, the performance was still considerably worse than our regression 
model. 
 
Molecular Indicators of Potency 
 
As the potency predicted from our model was in excellent agreement with the experimental data 
and retained accuracy against the test set (Fig 3), the 4 specific features used in the predictive 
model were investigated in detail. These features indicate physical properties and interactions 
implicated in molecular mechanism of resistance. The weight of the feature in the regression 
model are provided in Table 1.  The feature, that showed the strongest relationship with potency 
was the vdW interaction between the distal protease residues 12B-13B. In all but 2 variants, 
residue 12 is a threonine whereas residue 13 is either an isoleucine (WT) or a valine.(Figure S1) 
At first this result appears confounding, as these two residues neither make direct contact with 
the inhibitor nor face each other. However, a decrease in short-range interactions between 
residues 12 and 13 correlates strongly with decreased DRV binding affinity, consistently in both 
training and test sets. (Fig. 4) As these two residues are adjacent to each other, the loss of 
interactions can be explained by either a mutation or changes in relative sidechain orientation. If 
the effect was purely an indicator of amino acid identity, the feature would have been eliminated 
during feature selection, thus the orientation of the side chains of residues 12 and 13 are 
predictive for DRV affinity. Residue 13 is a common polymorphic mutation in other (non-B) HIV 
subtypes and the preexistence of 13V in treatment-naïve viral populations can lower the genetic 
barrier to resistance. (37) To identify whether the side chain orientation of these two residues 
relates to changes in specific molecular interactions, all features were regressed against vdW 
12B-13B. Features that showed a strong linear relationship with vdW 12B-13B (r2 ≥ 0.65) were in 
the immediate physical vicinity on the protein structure and mostly encoded for vdW interactions 
between 13B and other hydrophobic residues , suggesting that vdW 12B-13B acts as an indicator 
of the packing in the hydrophobic core, which as we and others previously suggested is 
reorganized due to resistance. (30, 31, 38) 
 
A similar trend was observed for the vdW interactions between residues 10B and 24B. Changes in 
these interactions were coupled with a weakening of the backbone hydrogen bond between 
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residues 9B and 24B, which in turn correlated with changes in both vdW and hydrogen bond 
interactions in the active site. Of note is that vdW 10B-24B and vdW 12B-13B were associated with 
changes in two different regions of the enzyme, suggesting that these features are indicative of 
distinct rearrangements.  
 
The third feature involved vdW interactions within the active site, between residues 50B-84A. Both 
residues are prominent sites of drug resistance mutations (I50V/L and I84V) which can contribute 
significantly to weakening inhibitor interactions. Residue 50 is located on the tip of the protease 
“flap”, the anti-parallel beta sheet acting as a gate to the active site. Sidechain of residue 50B 
contacts the side chain of residue 84A, across the dimer interface. Decreased vdW interactions 
between these two residues are associated with a loss of potency and indicate weakening of the 
inhibited, closed form of the enzyme and the slight opening of the “B” monomer flap. Changes in 
vdW 50B-84A interactions were only weakly related to other changes throughout the enzyme. 
However, the interactions may also be affected by other mutations, because the most significant 
loss in 50B-84A interactions was observed in variants that had only the I84V mutation, whereas 
variants that had mutations at both I50 and I84 mutations showed only a moderate change in 
interactions. Thus, distal mutations can propagate effects to the active site to weaken the critical 
residue 50-84 interactions that are indicative of closed flap (or inhibited) conformation. 
 
The final interaction included in the model was the hydrogen bond between the catalytic aspartic 
acids and DRV. Loss of this pivotal hydrogen bond was associated with a decrease in inhibitor 
binding. Decreased interactions with the catalytic aspartates have in the past been implicated to 
play a role in resistance against HIV-1 protease inhibitors. (39, 40) Our results reinforce these 
findings and display a linear relationship between DRV binding and the stability of the D25 
hydrogen bond. Overall we identified select and specific interactions indicative of concerted 
rearrangements in the hydrophobic core of the enzyme (vdW 10B-24B and vdW 12B-13B), 
changes in the active site (vdW 50B-84A), and interactions with the bound inhibitor (HBond D25); 





Thorough understanding of the molecular mechanisms of resistance is critical for the design of 
inhibitors that can avoid resistance and retain potency against rapidly evolving disease targets. 
Here we demonstrate that combining molecular dynamics and machine learning enables 
generating predictive models that identify molecular interactions indicative of decreased inhibitor 
affinity due to resistance over a wide range of potency. Molecular dynamics simulations and 
analysis of structural and dynamic features can quantify changes in molecular interactions; 
however, selecting a set of parameters that describe and predict inhibitor potency remains 
challenging. Here we developed a machine learning protocol that generated a predictive model of 
potency from merely 4 physical features. The predicted change in potency was in very good 
agreement with experimental values, outperforming MM/GBSA calculations. Furthermore, the 
model retained accuracy against a test set of variants not used in the training process, 
demonstrating the ability to generalize the model to unseen data. Many protease variants had 
vastly different (Fig. S1) combinations of mutations yet resistant variants ultimately converged to 
the same  molecular feature phenotypes. Critically, the predictive accuracy of our model over 
these variants indicates that drug resistance is mediated through conserved and specific 
mechanisms that are independent of the particular sites of mutations and can be characterized by 
select few molecular interactions. Due to the feature selection and design of the machine learning 
protocol, this correlation is not a mere indicator of changes in amino acid sequence, but rather 
reflects alterations in molecular interactions and dynamics of the enzyme inhibitor complex. 
Perhaps more importantly, these conserved interactions can be used to predict potency of novel 
inhibitors with improved resistance profiles. 
 
.CC-BY-NC-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a





Proteins, in particular enzymes, are dynamic molecules recognizing substrates, processing and 
releasing products. When an enzyme is a quickly evolving drug target, resistance emerges such 
that the balance of recognition favors the dynamics of substrate binding over inhibition. Thus, to 
elucidate the underlying mechanisms of drug resistance, assessing molecular dynamics is 
essential. Mutations in resistant variants of enzymes that are targeted with therapeutics occur 
throughout the structure both within the active site and at distal positions. Primary resistance 
mutations at the active site can effectively be explained by the substrate envelope model, where 
the mutation preferentially weakens inhibitor binding. (8) However, explaining how distal 
mutations confer resistance is more challenging. In our study of HIV-1 protease we have 
demonstrated how the dynamics of the enzyme is impacted by a combination of distal and active 
site mutations (19, 22, 23), and here comprehensive analysis with machine learning identified 
conserved mechanisms by which resistance occurs.  
 
Distal mutations cause resistance in many therapeutic target enzymes. These include kinases 
such as BCR-ABL with at least 19 mutations implicated in resistance (41), and EGFR with 13 
sites of resistance characterized (42-46). In antibacterials, sequence changes can cause potency 
loss, such as variants of dihydrofolate reductase resistant to the widely used drug trimethoprim 
(47-49). Variations in sequence including those distal from the active site can also be critical for 
development of pan-viral inhibitors against diseases such as those caused by flaviviruses 
(Dengue, Zika and Yellow Fever), and coronaviruses such as SARS-CoV, MERS-CoV and 
SARS-CoV-2. In addition, variations distal from the active site are key when developing specific 
inhibitors for a certain enzyme in a family, with identical active sites. Thus, methods to assess 
structural and dynamic features impacted by not only the active site but also distal mutations are 
required in many drug design applications. Combining parallel MD with machine learning to 
identify key bellwethers of potency will likely become a powerful strategy in drug design.  
 
 
Materials and Methods 
 
The code to calculate molecular features, the full set of features and the regression analysis are 




HIV-1 protease variants and experimental inhibitor potency 
Drug resistant variants of HIV-1 protease were obtained from viral passaging experiments with 
DRV and closely related analogs. (50) These variants were supplemented with variants bearing 
known primary active site mutations. The crystal structures of wild type protease, variants with 
primary resistance mutations, and highly drug resistant variants bound to DRV had been 
determined previously. (24, 51) The experimental Ki measurements were converted into free 
energy values using R×T×log(Ki), where R is the gas constant in kcal*K-1*mol-1. The temperature 
was set to 300 K. To supplement the set of in-house variants, a set of resistant variants from the 
literature was curated. The set was compiled to resemble the spread in free energy values 
observed in the in-house dataset. For this test set, inhibition constant reported in the primary 
reference were used. (Table S1)  
 
Structure preparation 
Protein–inhibitor complex structures were retrieved from the PDB. (52) When DRV was found in 
multiple conformations, we chose the conformation with the highest mean occupancy or the first 
conformation listed in PDB file in cases of equal occupancy. In one crystal structure (3ucb; Table 
1) a second molecule of DRV was co-crystallized outside of the active site and was removed for 
this analysis. All variants from viral passaging (Source: (50), Table1) that lacked experimental 
structures were modeled using Prime. (53, 54) 
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Structures were prepared using the Schrödinger Protein Preparation Wizard. (55) The protonation 
states were calculated using Propka. Protonation of the two catalytic aspartate residues, which 
exist primarily in the monoprotonated form, was examined and, if necessary, adjusted using the 
pKa values predicted by Propka to determine which of the two aspartic acids was protonated. (56, 
57) If necessary, the chain ID of the two monomers were exchanged to ensure uniformity: in all 
structures chain B was contacting the aniline moiety of DRV whereas chain A was contacting the 
bis-THF moiety. (e.g. Fig. 4) 
 
Molecular Dynamics Simulations  
For each variant, three 100 ns simulations with randomized starting velocities were performed. 
The details of molecular dynamics simulation protocol have been described previously. (58) In 
short, forcefield parameters were assigned using the OPLS3 forcefield. (55, 59) The protein–
inhibitor complex was solvated in a cubic box leaving at least 15 Angstrom between any solute 
atom and the periodic boundaries using the TIP3P water model. (60) Charges were neutralized 
by adding Na+ and Cl-, additional counterions were added up to concentration of 0.15 M. 
Thereafter the system was minimized in a series of steps. Simulations were run for 110 ns, where 




Loss in inhibitor binding are a consequence of alterations in structure and in conformational 
dynamics. To quantify these changes and correlate them with the experimental enzyme inhibition, 
we calculated descriptors of protein-inhibitor and protein-protein interactions and dynamics. 
Python scripts to calculate the descriptors were developed in house and can be obtained from the 
accompanying Github repository. 3D coordinates from molecular dynamics trajectories were 
parsed using the Schrodinger Python api. The exact descriptors are detailed in the following 
section. 
 
Van der Waals interactions 
Pairwise van der Waals interactions between all protein residues and between protein and 
inhibitor residues were calculated from molecular dynamics simulations with 1 ns intervals. The 
OPLS3 forcefield parameters were used and calculations followed the standard combination and 
exclusion rules used with the OPLS force field. (59, 61) 
 
Hydrogen bonds 
Inter- and intra-molecular hydrogen bond frequencies were calculated according to the geometric 
criteria defined in Steiner et al. (62) Water-mediated hydrogen bonds, that is hydrogen bonds 
between a solute atom, a solvent molecule and a third solute atom were also considered. All 
pairwise interactions were summed to residue-wise interactions. 
 
Torsion angle entropy 
To quantify torsion angle dynamics, a histogram of the ligand torsion angles and the φ and ψ 
angle distributions were constructed using a 36° bin width. The conformational entropy was 
calculated in terms of Shannon entropy. (63)  
 





Here N=10 is the number of bins and pi is the fraction of frames (from MD simulations) in which a 
torsion angle was in the configuration described by the ith bin. The base of the logarithm defines 
the limits of the entropy distribution. Here the natural logarithm was used. 
 
Root mean squared fluctuations 
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Root-mean-squared fluctuations (RMSF) of the protein C-alpha atoms, and root mean square 




All calculated features were transformed to Z-scores (Equation 2) by subtracting the feature mean 
(µ) and dividing by the standard deviation (σ). Z-scores of the final test set and the cross-








The objective of the feature selection protocol was to identify a sparse set of informative features, 
from which a model of the relationship between changes in physical interactions, dynamics and 
inhibitor binding can be established. Thus, we first identified the subset of features that are 
specific and informative. 
 
Specificity 
For each molecular feature that involved at least one variable protein residue, a regression model 
was constructed and compared with a competing null model. The null model was trained on a 
binary feature vector, with a value of 0 indicating an amino acid substitution relative to the NL4-3 
wildtype. When the molecular feature involved 2 variable residues, the null model was trained on 
a n×2 feature matrix where n is datapoints. The models were compared using the Akaike 
information criterion (AIC).  
 
 𝐴𝐴𝐴𝐴𝐴𝐴 = 2𝑘𝑘 − 2𝑙𝑙 𝑛𝑛(ℒ(𝜃𝜃|𝑥𝑥)) [3] 
 
Here ℒ is the maximum likelihood value of the model given a set of parameters θ and k is the 
number of parameters. The relative likelihood of the competing models can thus be calculated 
using: 
 
 𝑝𝑝 = 𝑒𝑒
𝐴𝐴𝐴𝐴𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚−𝐴𝐴𝐴𝐴𝐴𝐴𝑚𝑚
2  [4] 
 
If the relative likelihood of the null model was below 0.05, the molecular feature was assumed to 
be specific. This means neither that molecular features that fail this test only encode for sequence 
information, nor does it mean that molecular features that are determined to be specific do not 
also encode for sequence information; however, the specific features capture more information 
than the sequence alone. The null model test was used only when the molecular features did not 
include the inhibitor.  
 
Sparsity 
The Scikit-Learn implementation of elastic net regression was used to reduce the high 
dimensional set of parameters obtained from molecular dynamics simulations. (64, 65). An L1-
ratio of 0.75 and an alpha value of 1.0 were used. The elastic net model was trained on 66.6% of 
the training data. Training was repeated 100 times with different permutations of the training set. 
This was done to evaluate the stability of the coefficients. All non-zero (p<0.05, 1 sample t-test) 
coefficients were ranked according to their mean absolute values and a subset of parameters 
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For the p selected features the relationship with the potency of the N points in the dataset was 
modeled using a linear model:  





Where X is the N×p matrix of the selected features, βi is the coefficients of feature xi and β0 is the 
intercept. All possible combinations of the selected features were evaluated, and the models were 
compared using the Akaike information criterion. (Eq. 3 and Eq. 4). The statsmodels 
implementation of ordinary least squares regression and AIC were used. (66) All models with a 
relative likelihood of >0.05 were considered equivalent to the best model and among these the 
model with the fewest parameters was chosen. 
 
Model evaluation  
 
Model performance on the training/validation set was evaluated using root-mean-square error 
(RMSE): 
 𝑅𝑅𝑅𝑅𝑆𝑆𝑅𝑅 =  �
1
𝑁𝑁














and Spearman correlation: 
 
 







where N is the number of datapoints, f(x) is the prediction based on the independent variables x, 
y is the vector of dependent variables, cov(f(x), y) is the joined covariance, and 𝜎𝜎𝑓𝑓(𝑥𝑥)𝜎𝜎𝑦𝑦 are the 
standard deviations. In the case of Spearman correlation, the prefix “r” indicates that the 
continuous variables were transformed into ranks. In addition to the above metrics, the coefficient 
of determination (r2) was used to evaluate the goodness of a fit, where r2 is the square of ρpearson 




100 snapshots were extracted from MD simulations at 1 ns intervals. Previous studies of HIV-1 
protease inhibitors using endpoint free energy calculations have employed similar sampling with 
simulation times between 4 and 60 ns simulations. (35, 36, 67) Once water molecules and 
counterions had been removed, MM/GBSA calculations were carried out using “prime_mmgbsa” 
as implemented in the Schrödinger 2018-1 release (68). Results were given from the single 
starting structure and averaged over the 100 snapshots from each trajectory. The reported mean 
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Figure 1. Amino acid sequence variation and distribution in the HIV-1 protease variants: A) 
Sequence logo showing all residues with one or more amino acid substitution. B) Structure of 
HIV-1 in complex with darunavir (PDB ID: 6dgx). Protease shown as light blue cartoon. Sites of 
mutations highlighted in purple. Inhibitor and the catalytic aspartic acids displayed as sticks C) 
Hierarchical clustering of the HIV-1 protease variants according to sequence identity. 
Dendrogram shown on the left, dissimilarity matrix in the center, and darunavir potency for each 
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Figure 2. Molecular features indicative of inhibitor potency A) Absolute coefficients averaged 
over 100 rounds of shuffle-split cross validation. 9 features have coefficients larger than 0.02 
(dashed horizontal line) B) Hierarchical clustering of the top 9 features according to coefficients 
C) Features with top 9 coefficients mapped onto the structure of protease–DRV complex. vdW 
interactions shown in orange, RMSF in yellow, torsion angle in blue and hydrogen bond in purple. 
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Figure 3. A) Evaluation of the regression model on training (purple dots) and test (orange dots) 
sets for prediction of DRV potency with only 4 features. Error bars indicate the 95% confidence 
interval. Training set metrics were calculated using 5-fold cross validation. B) Fit with 
experimental data. The correlation values for MM/GBSA correspond to the single frame and full 
trajectory results. C) MM/GBSA binding free energy of DRV against training and test sets 
averaging 3 snapshots from the trajectory. D) MM/GBSA binding free energy of DRV against 
training and test sets averaging the entire trajectory. Error bars correspond to the 95% confidence 
interval estimated from the 3 simulation replicates.  
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Figure 4. Signature interactions mapped onto the structure of HIV-1 protease. DRV shown in 
beige sticks. Insets show linear regression curves for each feature, with training set datapoints 
shown as squares and test set datapoints shown as circles. Dark blue: vdW interactions between 
residues 50B and 84A; Purple: the hydrogen bond between the catalytic residue D25 and DRV; 
Green: vdW interactions between residues 10B and 24B; and Orange: vdW interactions between 
residues 12B and 13B. 
 
  
.CC-BY-NC-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a





Table 1. Ordinary least squares model (Eq. 5) of DRV binding as a function of intra- and 
intermolecular interactions. β are the coefficients, σ the standard deviation and p the probability of 
H0: β=0T. 
 
 β σ p 
intercept -11.50 0.16 0.0 
vdW 10B-24B -0.58 0.17 0.005 
vdW 12B-13B 0.73 0.20 0.003 
vdW 50B-84A 0.59 0.23 0.02 
HBond D25 -0.55 0.24 0.04 
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